AOL

Medicare and Reclast infusion: Is it covered?

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...
FierceBiotech

FDA approves Reclast to prevent osteoporosis in postmenopausal women with convenient less frequent dosing

Single infusion of Reclast increases bone mass for two years in postmenopausal women with osteopenia, a condition that can lead to osteoporosis[1] Approximately 22 million women in US have osteopenia, ...
FierceBiotech

Press Release: Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis

Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis Study of over 7,700 women published today shows reduction of 70 percent in spine fractures and 41 ...
Fierce Healthcare

Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocor

EAST HANOVER, N.J., April 11 /PRNewswire/ -- New data show that a once-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg was significantly better than risedronate at increasing bone mass ...
EurekAlert!

FDA approves Reclast -- the first and only once-yearly treatment for postmenopausal osteoporosis

The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...
Medindia

Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis

EAST HANOVER, N.J., Oct. 16 Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast® (zoledronic acid) injection in postmenopausal ...
Monthly Prescribing Reference

Reclast approved for biennial dosing regimen to prevent female osteoporosis

The FDA has approved Reclast (zoledronic acid, from Novartis) injection for the prevention of osteoporosis in women for two years with a single dose. This approval was based on a study involving more ...
East Bay Times

Once-a-year treatment for bone loss is promising

A simple annual infusion of a new drug is just as effective at reducing bone fractures as weekly or monthly bone loss drugs currently on the market, according to a study by researchers at the ...
The Telegraph

Reclast infusions bring on rare side effect of severe joint pain

DEAR DR. ROACH: For the last few years, I have been taking yearly Reclast infusions for osteoporosis, because I have trouble taking oral medications of any kind. The infusion was given in February ...
Medindia

Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids

EAST HANOVER, N.J., April 11 New data show that aonce-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg wassignificantly better than risedronate at increasing bone mass in patients ...
Sun Journal

Reclast infusions bring on rare side effect of severe joint pain

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: For the last few years, I have been taking yearly Reclast ...